Syndax Pharmaceuticals (FRA:1T3) Other Current Receivables: €19.5 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1T3 Syndax Pharmaceuticals Inc FRA:1T3
20 GF Score
Price €18.50
! 7 Warning Signs
View Full Analysis

What is Syndax Pharmaceuticals Other Current Receivables?

Syndax Pharmaceuticals FRA:1T3 -3.12% 20 Other Current Receivables is €19.5 Mil as of Mar. 2026. GuruFocus rates FRA:1T3 with a GF Score™ of 20/100. The stock has 7 warning signs investors should review.

Syndax Pharmaceuticals's Other Current Receivables for the quarter that ended in Mar. 2026 was €19.5 Mil.

Syndax Pharmaceuticals's quarterly Other Current Receivables increased from Sep. 2025 (€1.64 Mil) to Dec. 2025 (€27.58 Mil) but then stayed the same from Dec. 2025 (€27.58 Mil) to Mar. 2026 (€19.53 Mil).

Syndax Pharmaceuticals's annual Other Current Receivables increased from Dec. 2023 (€1.13 Mil) to Dec. 2024 (€5.99 Mil) and increased from Dec. 2024 (€5.99 Mil) to Dec. 2025 (€27.58 Mil).

Syndax Pharmaceuticals Other Current Receivables Related Terms

Syndax Pharmaceuticals Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Syndax Pharmaceuticals's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syndax Pharmaceuticals Other Current Receivables Chart

Syndax Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 0.55 1.13 5.99 27.58

Syndax Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.33 4.90 1.64 27.58 19.53
FRA:1T3
20GF Score
Syndax Pharmaceuticals Inc FRA:1T3
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syndax Pharmaceuticals Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €19.5 Mil mean?
Syndax Pharmaceuticals (FRA:1T3) has a Other Current Receivables of €19.5 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Syndax Pharmaceuticals and its competitors.
Is Syndax Pharmaceuticals' Other Current Receivables too high?
Syndax Pharmaceuticals' current Other Current Receivables is €19.5 Mil. Overall, Syndax Pharmaceuticals has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Other Current Receivables compare to IOVA and GLUE?
Syndax Pharmaceuticals' Other Current Receivables of €19.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Syndax Pharmaceuticals and its competitors. Syndax Pharmaceuticals's current Other Current Receivables is €19.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (FRA:1T3) has a current Other Current Receivables of €19.5 Mil. The current Other Current Receivables is €19.5 Mil. Syndax Pharmaceuticals' overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current Other Current Receivables is €19.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syndax Pharmaceuticals Business Description

Other Exchanges SNDX:USA1T3:Germany
Address 730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
20GF Score

Get the complete analysis for FRA:1T3

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.50
Price